Vitamin D analogs: Actions and role in the treatment of secondary hyperparathyroidism

González, 1995, Renal osteodystrophy, Nephrol Dial Transplant, 10, 13, 10.1093/ndt/10.supp3.13 Slatopolsky, 1999, Pathogenesis of secondary hyperparathyroidism, Kidney Int Suppl, 73, S14, 10.1046/j.1523-1755.1999.07304.x Slatopolsky, 2001, Role of phosphorus in the pathogenesis of secondary hyperparathyroidism, Am J Kidney Dis, 37, S54, 10.1053/ajkd.2001.20740 Silver, 1986, Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat, J Clin Invest, 78, 1296, 10.1172/JCI112714 Russell, 1986, Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene, Endocrinology, 119, 2864, 10.1210/endo-119-6-2864 Cantley, 1985, 1,25-dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture, Endocrinology, 117, 2114, 10.1210/endo-117-5-2114 Kremer, 1989, Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells, Endocrinology, 125, 935, 10.1210/endo-125-2-935 Andress, 1989, Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure, N Engl J Med, 321, 274, 10.1056/NEJM198908033210502 Slatopolsky, 1984, Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients, J Clin Invest, 74, 2136, 10.1172/JCI111639 Quarles, 1994, Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD, Kidney Int, 45, 1710, 10.1038/ki.1994.223 Delmez, 1992, Hyperphosphatemia, Am J Kidney Dis, 19, 303, 10.1016/S0272-6386(12)80446-X Brown, 1999, Vitamin D analogs, Miner Electrolyte Metab, 25, 337, 10.1159/000057470 Slatopolsky, 1995, A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia, Am J Kidney Dis, 26, 852, 10.1016/0272-6386(95)90455-7 Finch, 1999, Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone, J Am Soc Nephrol, 10, 980, 10.1681/ASN.V105980 Takahashi, 1997, A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content, Am J Kidney Dis, 30, 105, 10.1016/S0272-6386(97)90571-0 Martin, 1998, 19-Nor-1-a-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact PTH in patients on hemodialysis, J Am Soc Nephrol, 9, 1427, 10.1681/ASN.V981427 Lindberg, 2001, A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease, Clin Nephrol, 56, 315 Martin, 1998, Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2, Am J Kidney Dis, 32, S61, 10.1053/ajkd.1998.v32.pm9808145 Coyne, 2002, Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients, Am J Kidney Dis, 40, 1283, 10.1053/ajkd.2002.36899 Sprague, 2001, Suppression of parathyroid hormone secretion in hemodialysis patients, Am J Kidney Dis, 38, S51, 10.1053/ajkd.2001.28110 Teng, 2003, Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy, N Engl J Med, 349, 446, 10.1056/NEJMoa022536 Kobayashi, 1994, The binding properties, with blood proteins, and tissue distribution of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a noncalcemic analogue of 1 alpha, 25-dihydroxyvitamin D3, in rats, J Biochem (Tokyo), 115, 373, 10.1093/oxfordjournals.jbchem.a124346 Okano, 1989, Protein-binding properties of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a synthetic analogue of 1 alpha,25-dihydroxyvitamin D3, J Nutr Sci Vitaminol (Tokyo), 35, 529, 10.3177/jnsv.35.529 Dusso, 1991, On the mechanisms for the selective action of vitamin D analogs, Endocrinology, 128, 1687, 10.1210/endo-128-4-1687 Yasuda, 2003, Multicenter clinical trial of 22-oxa-1,25-dihydroxyvitamin D3 for chronic dialysis patients, Am J Kidney Dis, 41, S108, 10.1053/ajkd.2003.50097 Akizawa, 2002, Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study, Nephrol Dial Transplant, 17, 28, 10.1093/ndt/17.suppl_10.28 Hirata, 2003, In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)(2) vitamin D(3), Nephrol Dial Transplant, 18, 1770, 10.1093/ndt/gfg296 Monier-Faugere, 1999, 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure, Kidney Int, 55, 821, 10.1046/j.1523-1755.1999.055003821.x Tsukamoto, 2000, Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism, Am J Kidney Dis, 35, 458, 10.1016/S0272-6386(00)70198-3 Komuro, 1999, In vivo and in vitro pharmacokinetics and metabolism studies of 26,26,26,27,27,27-F6-1,25(OH)2 vitamin D3 (Falecalcitriol) in rat, Xenobiotica, 29, 603, 10.1080/004982599238425 Akiba, 1998, Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism, Am J Kidney Dis, 32, 238, 10.1053/ajkd.1998.v32.pm9708607 Ritzerfeld, 2001, Alfacalcidol in the therapy of renal bone disease, Int J Clin Pharmacol Ther, 39, 546, 10.5414/CPP39546 Avioli, 1999, Vitamin D and the D-hormones, alfacalcidol and calcitriol, as therapeutic agents for osteoporotic populations, Calcif Tissue Int, 65, 292, 10.1007/s002239900701 Hamdy, 1995, Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure, BMJ, 310, 358, 10.1136/bmj.310.6976.358 Lee, 1994, A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism, J Am Soc Nephrol, 5, 1344, 10.1681/ASN.V561344 Sharman, 1982, Long-term experience of alfacalcidol in renal osteodystrophy, QJM, 51, 271 Sjoden, 1985, 1 alpha-Hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat, Proc Soc Exp Biol Med, 178, 432, 10.3181/00379727-178-42028 Sjoden, 1984, Antirachitic activity of 1 alpha-hydroxyergocalciferol and 1 alpha-hydroxycholecalciferol in rats, J Nutr, 114, 2043, 10.1093/jn/114.11.2043 Mawer, 1998, Unique 24-hydroxylated metabolites represent a significant pathway of metabolism of vitamin D2 in humans, J Clin Endocrinol Metab, 83, 2156, 10.1210/jc.83.6.2156 Frazao, 2000, Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism, Am J Kidney Dis, 36, 550, 10.1053/ajkd.2000.16193 Maung, 2001, Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism, Am J Kidney Dis, 37, 532, 10.1016/S0272-6386(01)80010-X